SLS — SELLAS Life Sciences Group, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1390478 ·
Last close
$19.15
Market Cap
$3.90B
52W High
$24.89
52W Low
$1.39
ADV30
10,839,478
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -11,309,000 | -10,091,000 | 141,091,000 | 134,711,000 | 9,286,000 |
| Jun 2026 | 0 | — | -10,629,000 | -9,605,000 | 145,382,000 | 138,343,000 | 7,726,000 |
| Mar 2026 | 0 | — | -9,252,000 | -8,407,000 | 114,177,000 | 107,097,000 | 6,765,000 |
| Dec 2025 | 0 | — | -8,255,000 | -7,658,000 | 78,345,000 | 71,793,000 | 7,474,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,423,000
Investing CF
—
Financing CF
$141,469,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.23
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-293,000,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-35,219,000
Pretax Income TTM
$-32,461,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,274,000 | -26,863,000 | 78,345,000 | 7,474,000 | 70,871,000 | -28,389,000 |
| Dec 2024 | 0 | -31,513,000 | -30,881,000 | 19,432,000 | 9,967,000 | 9,465,000 | -35,402,000 |
| Dec 2023 | 0 | -37,869,000 | -37,340,000 | 6,219,000 | 14,195,000 | -7,976,000 | -31,410,000 |
| Dec 2022 | 1,000,000 | -31,950,000 | -41,301,000 | 20,943,000 | 16,092,000 | 4,851,000 | -23,809,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$37,468,000
NetIncome TTM
$-32,461,000
OpCashFlow TTM
—
Assets (Latest)
$145,382,000
Forward EPS
$-0.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc. | $3.81B | $38.78 | — |
| TNGX | Tango Therapeutics, Inc. | $3.75B | $22.11 | — |
| OGN | Organon & Co. | $3.65B | $13.90 | — |
| ABCL | AbCellera Biologics Inc. | $3.60B | $11.03 | — |
| INDV | Supernus, Inc. | $4.28B | $36.28 | — |
News headlines (Yahoo Finance, 1h cache)
SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here
2026-11-18 02:41 · Yahoo
SELLAS Stock In Focus After Phase 3 AML Trial Win
2026-11-18 00:18 · Yahoo
Sellas Life Sciences stock falls on $150M stock offering
2026-11-17 22:17 · Yahoo
Another Cancer Vaccine Just Scored A Home Run; Shares Catapult 150%
2026-11-17 21:33 · Yahoo
SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering
2026-11-17 21:01 · Yahoo
Sellas Life Sciences shares surge 175% after cancer vaccine succeeds in late-stage trial
2026-11-17 16:20 · Yahoo
SELLAS Life Sciences stock soars 240% on positive cancer trial
2026-11-17 14:12 · Yahoo
Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027
2026-11-17 12:59 · Yahoo
SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaning
2026-11-17 12:00 · Yahoo
SLS Stock Jumps After-Hours: Retail Eyes Lilly’s Cancer Deal for Valuation Clues — 2 Big Investors Grab Shares
2026-11-17 01:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.